Literature DB >> 23238216

NK cytolysis is dependent on the proportion of HLA-G expression.

Bao-Guo Chen1, Dan-Ping Xu, Aifen Lin, Wei-Hua Yan.   

Abstract

The suppressive functions of HLA-G to various immune cells have been well established. The proportion of HLA-G expression in malignant lesion cells was found from negative to 100%. However, effects for the different proportion of HLA-G expression on the cytolysis of NK cells remain to be explored. In this study, NK cytolysis to the various proportion of HLA-G1 expression on leukemia cell line K562 was investigated. Analysis of NK cell cytotoxicity was by detecting the NK cell surface CD107a expression. Data showed that NK cell cytolysis could be inhibited by the HLA-G1 expression and in a manner of HLA-G1 expression proportion dependent manner (r = 0.925, p = 0.008). Our study provided further understanding for the roles of HLA-G1 expression in malignant cell immune escaping from NK cells.
Copyright © 2012 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23238216     DOI: 10.1016/j.humimm.2012.12.005

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  16 in total

1.  Epigenetic modification augments the immunogenicity of human leukocyte antigen G serving as a tumor antigen for T cell-based immunotherapy.

Authors:  Kei Ishibashi; Takumi Kumai; Takayuki Ohkuri; Akemi Kosaka; Toshihiro Nagato; Yui Hirata; Kenzo Ohara; Kensuke Oikawa; Naoko Aoki; Naoko Akiyama; Masatoshi Sado; Masahiro Kitada; Yasuaki Harabuchi; Esteban Celis; Hiroya Kobayashi
Journal:  Oncoimmunology       Date:  2016-03-30       Impact factor: 8.110

2.  Human Leukocyte Antigen-G (HLA-G) Expression in Cancers: Roles in Immune Evasion, Metastasis and Target for Therapy.

Authors:  Aifen Lin; Wei-Hua Yan
Journal:  Mol Med       Date:  2015-08-24       Impact factor: 6.354

Review 3.  HLA Class Ib Molecules and Immune Cells in Pregnancy and Preeclampsia.

Authors:  Snezana Djurisic; Thomas Vauvert F Hviid
Journal:  Front Immunol       Date:  2014-12-23       Impact factor: 7.561

4.  Rescuing lymphocytes from HLA-G immunosuppressive effects mediated by the tumor microenvironment.

Authors:  Danli Wu; Isere Kuiaste; Philippe Moreau; Edgardo Carosella; Patricia Yotnda
Journal:  Oncotarget       Date:  2015-11-10

5.  Predictive value of different proportion of lesion HLA-G expression in colorectal cancer.

Authors:  Rui-Li Zhang; Xia Zhang; Shan-Shan Dong; Bing Hu; Qiu-Yue Han; Jian-Gang Zhang; Wen-Jun Zhou; Aifen Lin; Wei-Hua Yan
Journal:  Oncotarget       Date:  2017-11-18

6.  Clinical Significance of Potential Unidentified HLA-G Isoforms Without α1 Domain but Containing Intron 4 in Colorectal Cancer Patients.

Authors:  Aifen Lin; Xia Zhang; Rui-Li Zhang; Jian-Gang Zhang; Wen-Jun Zhou; Wei-Hua Yan
Journal:  Front Oncol       Date:  2018-09-04       Impact factor: 6.244

Review 7.  Heterogeneity of HLA-G Expression in Cancers: Facing the Challenges.

Authors:  Aifen Lin; Wei-Hua Yan
Journal:  Front Immunol       Date:  2018-09-27       Impact factor: 7.561

Review 8.  Intercellular transfer of HLA-G: its potential in cancer immunology.

Authors:  Aifen Lin; Wei-Hua Yan
Journal:  Clin Transl Immunology       Date:  2019-08-30

9.  Growth Hormone Stops Excessive Inflammation After Partial Hepatectomy, Allowing Liver Regeneration and Survival Through Induction of H2-Bl/HLA-G.

Authors:  Mayumi Ishikawa; Andrew J Brooks; Manuel A Fernández-Rojo; Johan Medina; Yash Chhabra; Shiro Minami; Kathryn A Tunny; Robert G Parton; Julian P Vivian; Jamie Rossjohn; Viral Chikani; Grant A Ramm; Ken K Y Ho; Michael J Waters
Journal:  Hepatology       Date:  2020-11-02       Impact factor: 17.425

10.  Intratumor Heterogeneity of HLA-G Expression in Cancer Lesions.

Authors:  Xia Zhang; Aifen Lin; Qiu-Yue Han; Jian-Gang Zhang; Qiong-Yuan Chen; Yao-Han Ye; Wen-Jun Zhou; Hui-Hui Xu; Jun Gan; Wei-Hua Yan
Journal:  Front Immunol       Date:  2020-11-19       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.